Početna stranicaOPHLF • OTCMKTS
add
Ono Pharmaceutical Co Ltd
VrijednosnicaPredvodnik u zaštiti okolišaZemlja u kojoj se trguje vrijednosnicom: SADZemlja u kojoj se nalazi sjedište: JP
Preth. zaklj. cijena
11,35 $
Godišnji raspon
10,26 $ - 18,17 $
Tržišna kapitalizacija
839,26 mlr. JPY
Prosječna količina
3,51 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
TYO
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 122,66 mlr. | −11,56 % |
Operativni troškovi | 70,27 mlr. | 45,14 % |
Neto dohodak | 16,85 mlr. | −60,52 % |
Neto profitabilnost | 13,73 | −55,38 % |
Zarada po dionici | — | — |
EBITDA | 29,81 mlr. | −50,52 % |
Efektivna porezna stopa | 21,18 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 177,04 mlr. | 64,35 % |
Ukupna imovina | 1,05 bil. | 16,80 % |
Ukupne obveze | 258,30 mlr. | 129,33 % |
Ukupni kapital | 788,11 mlr. | — |
Dionice u optjecaju | 469,71 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,01 | — |
Povrat imovine | 5,91 % | — |
Povrat kapitala | 6,53 % | — |
Tok novca
Neto promjena novca
(JPY) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 16,85 mlr. | −60,52 % |
Gotovina od poslovanja | 33,91 mlr. | −26,85 % |
Gotovina iz ulaganja | 4,27 mlr. | −85,73 % |
Gotovina iz financiranja | −2,17 mlr. | 92,55 % |
Neto promjena novca | 32,84 mlr. | −30,52 % |
Slobodan tok novca | 19,88 mlr. | −69,86 % |
Više
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Glavni izvršni direktor
Osnovano
1717
Sjedište
Web-lokacija
Zaposlenici
3.853